CRVS Earnings Date: Nov 3, 2026 (Estimated) — Corvus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is CRVS's next earnings date?
Corvus Pharmaceuticals, Inc. (CRVS) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.19.
How did CRVS do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Corvus Pharmaceuticals, Inc. posted EPS of -$0.19 versus the -$0.16 estimate, a miss of 11.8%. Revenue was $0. The stock's 1-day post-earnings move was +0.4%.
How much does CRVS stock move after earnings?
CRVS beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.5% (up or down) in the day after earnings.
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.16 | -0.19 | -11.76% | $0 | ❌ Miss | +0.43% | +9.24% | +3.82% |
| 2026-05-07 | Q1 2026 | -0.15 | -0.15 | +0.00% | $0 | ➖ Inline | +6.58% | -6.41% | -23.58% |
| 2026-03-12 | Q4 2025 | -0.14 | -0.15 | -7.14% | $0 | ❌ Miss | -4.31% | -11.99% | -5.25% |
| 2025-11-04 | Q3 2025 | -0.14 | -0.12 | +14.29% | $0 | ✅ Beat | -1.44% | +6.94% | +15.31% |
| 2025-08-07 | Q2 2025 | -0.13 | -0.10 | +23.08% | $0 | ✅ Beat | +4.36% | +17.43% | +42.86% |
| 2025-03-25 | Q4 2024 | -0.12 | -0.18 | -50.00% | $0 | ❌ Miss | -14.76% | -19.34% | -6.87% |
| 2024-11-12 | Q3 2024 | -0.11 | -0.60 | -445.45% | $0 | ❌ Miss | +2.07% | -3.34% | -7.02% |
| 2024-08-06 | Q2 2024 | -0.12 | -0.07 | +41.67% | $0 | ✅ Beat | +9.67% | +25.17% | +33.33% |
Showing last 8 quarters.